Cargando…

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Salles, Gilles, Schuster, Stephen J., Fischer, Luca, Kuruvilla, John, Patten, Piers E. M., von Tresckow, Bastian, Smith, Sonali, Jiménez-Ubieto, Ana, Davis, Keith L., Nagar, Saurabh, Zhang, Jie, Bollu, Vamsi, Jousseaume, Etienne, Ramos, Roberto, Wang, Yucai, Link, Brian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263496/
https://www.ncbi.nlm.nih.gov/pubmed/35813099
http://dx.doi.org/10.1097/HS9.0000000000000745
_version_ 1784742745237094400
author Salles, Gilles
Schuster, Stephen J.
Fischer, Luca
Kuruvilla, John
Patten, Piers E. M.
von Tresckow, Bastian
Smith, Sonali
Jiménez-Ubieto, Ana
Davis, Keith L.
Nagar, Saurabh
Zhang, Jie
Bollu, Vamsi
Jousseaume, Etienne
Ramos, Roberto
Wang, Yucai
Link, Brian K.
author_facet Salles, Gilles
Schuster, Stephen J.
Fischer, Luca
Kuruvilla, John
Patten, Piers E. M.
von Tresckow, Bastian
Smith, Sonali
Jiménez-Ubieto, Ana
Davis, Keith L.
Nagar, Saurabh
Zhang, Jie
Bollu, Vamsi
Jousseaume, Etienne
Ramos, Roberto
Wang, Yucai
Link, Brian K.
author_sort Salles, Gilles
collection PubMed
description This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow-up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.
format Online
Article
Text
id pubmed-9263496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92634962022-07-08 A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL) Salles, Gilles Schuster, Stephen J. Fischer, Luca Kuruvilla, John Patten, Piers E. M. von Tresckow, Bastian Smith, Sonali Jiménez-Ubieto, Ana Davis, Keith L. Nagar, Saurabh Zhang, Jie Bollu, Vamsi Jousseaume, Etienne Ramos, Roberto Wang, Yucai Link, Brian K. Hemasphere Article This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow-up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL. Lippincott Williams & Wilkins 2022-06-21 /pmc/articles/PMC9263496/ /pubmed/35813099 http://dx.doi.org/10.1097/HS9.0000000000000745 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Salles, Gilles
Schuster, Stephen J.
Fischer, Luca
Kuruvilla, John
Patten, Piers E. M.
von Tresckow, Bastian
Smith, Sonali
Jiménez-Ubieto, Ana
Davis, Keith L.
Nagar, Saurabh
Zhang, Jie
Bollu, Vamsi
Jousseaume, Etienne
Ramos, Roberto
Wang, Yucai
Link, Brian K.
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title_full A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title_fullStr A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title_full_unstemmed A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title_short A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
title_sort retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (record-fl)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263496/
https://www.ncbi.nlm.nih.gov/pubmed/35813099
http://dx.doi.org/10.1097/HS9.0000000000000745
work_keys_str_mv AT sallesgilles aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT schusterstephenj aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT fischerluca aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT kuruvillajohn aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT pattenpiersem aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT vontresckowbastian aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT smithsonali aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT jimenezubietoana aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT daviskeithl aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT nagarsaurabh aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT zhangjie aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT bolluvamsi aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT jousseaumeetienne aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT ramosroberto aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT wangyucai aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT linkbriank aretrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT sallesgilles retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT schusterstephenj retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT fischerluca retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT kuruvillajohn retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT pattenpiersem retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT vontresckowbastian retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT smithsonali retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT jimenezubietoana retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT daviskeithl retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT nagarsaurabh retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT zhangjie retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT bolluvamsi retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT jousseaumeetienne retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT ramosroberto retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT wangyucai retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl
AT linkbriank retrospectivecohortstudyoftreatmentoutcomesofadultpatientswithrelapsedorrefractoryfollicularlymphomarecordfl